Advent Pharma Ltd. (DSE: ADVENT)
Bangladesh
· Delayed Price · Currency is BDT 16.80
+0.10 (0.60%)
At close: Dec 19, 2024
Advent Pharma Income Statement
Financials in millions BDT. Fiscal year is July - June.
Millions BDT. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | Jun '20 Jun 30, 2020 | 2019 - 2016 |
| Revenue | 522.06 | 571.67 | 558.05 | 530.47 | 503.6 | 534.03 | Upgrade
|
| Revenue Growth (YoY) | -6.51% | 2.44% | 5.20% | 5.34% | -5.70% | -11.29% | Upgrade
|
| Cost of Revenue | 319.7 | 343.77 | 335.14 | 310.31 | 288 | 307.64 | Upgrade
|
| Gross Profit | 202.36 | 227.9 | 222.91 | 220.16 | 215.61 | 226.39 | Upgrade
|
| Selling, General & Admin | 82.77 | 86.26 | 87.55 | 86.78 | 79.18 | 70.98 | Upgrade
|
| Operating Expenses | 82.77 | 86.26 | 87.55 | 86.78 | 79.18 | 70.98 | Upgrade
|
| Operating Income | 119.59 | 141.65 | 135.36 | 133.38 | 136.42 | 155.41 | Upgrade
|
| Interest Expense | -8.49 | -8.09 | -6.63 | -4.11 | -4.9 | -4.44 | Upgrade
|
| Interest & Investment Income | 0.02 | 0.02 | 0.01 | 1.1 | 2.93 | 8.83 | Upgrade
|
| Other Non Operating Income (Expenses) | -29.75 | -29.79 | -0.11 | -0.08 | 0.12 | 1.71 | Upgrade
|
| EBT Excluding Unusual Items | 81.36 | 103.78 | 128.63 | 130.3 | 134.58 | 161.51 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | - | -0.39 | - | Upgrade
|
| Pretax Income | 81.36 | 103.78 | 128.63 | 130.3 | 134.19 | 161.51 | Upgrade
|
| Income Tax Expense | 14.75 | 19.79 | 29.99 | 32.76 | 20.6 | 44.45 | Upgrade
|
| Net Income | 66.62 | 83.99 | 98.64 | 97.53 | 113.59 | 117.05 | Upgrade
|
| Net Income to Common | 66.62 | 83.99 | 98.64 | 97.53 | 113.59 | 117.05 | Upgrade
|
| Net Income Growth | -28.51% | -14.85% | 1.14% | -14.14% | -2.96% | -26.10% | Upgrade
|
| Shares Outstanding (Basic) | 93 | 93 | 93 | 93 | 93 | 93 | Upgrade
|
| Shares Outstanding (Diluted) | 93 | 93 | 93 | 93 | 93 | 93 | Upgrade
|
| EPS (Basic) | 0.72 | 0.90 | 1.06 | 1.05 | 1.22 | 1.26 | Upgrade
|
| EPS (Diluted) | 0.72 | 0.90 | 1.06 | 1.05 | 1.22 | 1.26 | Upgrade
|
| EPS Growth | -28.51% | -14.85% | 1.14% | -14.14% | -2.96% | -26.10% | Upgrade
|
| Free Cash Flow | 16.3 | 13.08 | 2.56 | -11.56 | -3.67 | -42.33 | Upgrade
|
| Free Cash Flow Per Share | 0.18 | 0.14 | 0.03 | -0.12 | -0.04 | -0.45 | Upgrade
|
| Dividend Per Share | 0.100 | 0.100 | 0.200 | 0.200 | 0.196 | - | Upgrade
|
| Dividend Growth | -50.00% | -50.00% | 0% | 1.99% | - | - | Upgrade
|
| Gross Margin | 38.76% | 39.87% | 39.94% | 41.50% | 42.81% | 42.39% | Upgrade
|
| Operating Margin | 22.91% | 24.78% | 24.26% | 25.14% | 27.09% | 29.10% | Upgrade
|
| Profit Margin | 12.76% | 14.69% | 17.68% | 18.39% | 22.56% | 21.92% | Upgrade
|
| Free Cash Flow Margin | 3.12% | 2.29% | 0.46% | -2.18% | -0.73% | -7.93% | Upgrade
|
| EBITDA | 185.04 | 207.57 | 193.96 | 175.07 | 174.59 | 188.53 | Upgrade
|
| EBITDA Margin | 35.45% | 36.31% | 34.76% | 33.00% | 34.67% | 35.30% | Upgrade
|
| D&A For EBITDA | 65.46 | 65.93 | 58.6 | 41.69 | 38.17 | 33.12 | Upgrade
|
| EBIT | 119.59 | 141.65 | 135.36 | 133.38 | 136.42 | 155.41 | Upgrade
|
| EBIT Margin | 22.91% | 24.78% | 24.26% | 25.14% | 27.09% | 29.10% | Upgrade
|
| Effective Tax Rate | 18.13% | 19.07% | 23.31% | 25.15% | 15.35% | 27.52% | Upgrade
|
| Advertising Expenses | - | 0.15 | 0.19 | 0.18 | 0.15 | 0.11 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.